Trial Condition(s):

Pulmonary hypertension

Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)

Bayer Identifier:

14184

ClinicalTrials.gov Identifier:

NCT01062282

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of this study is to gain information on safety and efficacy from Korean patients who starting Ventavis treatment by observational method.

Inclusion Criteria
- The treating physician has chosen Ventavis as a suitable treatment for the patient
 - Patient with PH and classified as NYHA functional class III or IV and WHO group 1
Exclusion Criteria
- Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis patient package insert).

Trial Summary

Enrollment Goal
41
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Ventavis (Iloprost, BAYQ6256)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, South Korea

Status
Completed
 

Trial Design